Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Dactylis glomerata pollen allergens are extracts from the pollen of the orchard grass (Dactylis glomerata) plant, primarily used in diagnostic testing and immunotherapy for grass pollen allergies. These allergens, including specific proteins like Dac g 3 and Dac g 4, trigger IgE-mediated immune responses leading to allergic rhinitis with or without conjunctivitis in sensitized individuals. They are key components in products like Oralair and standardized grass pollen extracts, approved for sublingual or injection use in patients aged 5-65 with confirmed sensitivity via skin tests or IgE assays. Poaceae family pollen allergens like these are classified by protein structure and function, contributing to seasonal allergies from atmospheric exposure. While not traditional therapeutic targets like receptors or enzymes, they serve as antigens in allergen-specific immunotherapy to induce tolerance and reduce symptoms. Safety concerns include heightened hypersensitivity risks when combined with certain drugs like beta-blockers.
6 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Dactylis glomerata pollen allergens.